The activation of some alternative pathways also protects AML cells and promotes drug resistance [14–16], and the TP53 apoptosis network is also involved as a medium to help AML cells resist BCL-2 inhibition [17]. The gene discussed is TP53; the disease is acute myeloid leukemia.